Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thiarabine

Drug Profile

Thiarabine

Alternative Names: 4'-Thio-Ara-C; 4-thio Ara-C; GS 7836; OSI 7836; SR 9025; T-araC; Thiocytosine arabinoside; VP700 series; VP701

Latest Information Update: 18 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Southern Research Institute
  • Developer Abeona Therapeutics
  • Class Antineoplastics; Arabinonucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Leukaemia; Rheumatoid arthritis

Most Recent Events

  • 28 Feb 2011 Phase-I development is ongoing in USA
  • 07 Jul 2009 Pharmacodynamics data from preclinical trials in Rheumatoid arthritis released by Access Pharmaceuticals
  • 04 Jun 2009 Pharmacodynamics data from a Preclinical trial in Cancer released by Access Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top